Trial Profile
Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing - the INSTAR Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Fluticasone propionate (Primary)
- Indications Asthma; Wheezing
- Focus Therapeutic Use
- Acronyms INSTAR
- 18 Mar 2024 Planned End Date changed from 1 May 2025 to 1 May 2028.
- 18 Mar 2024 Planned primary completion date changed from 1 May 2025 to 1 May 2026.
- 10 Jun 2020 Planned End Date changed from 1 May 2023 to 1 May 2025.